New vaccine aims to fight childhood brain tumors without surgery

NCT ID NCT02358187

Recruiting now Disease control Sponsor: James Felker Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a vaccine made from glioma antigen peptides combined with an immune booster (Poly-ICLC) in 25 children with recurrent low-grade gliomas that cannot be removed by surgery. The goal is to see if the vaccine can shrink tumors or keep them stable. Children who respond well may continue vaccinations for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glioma antigen peptides with Poly-ICLC
What this could lead to: If it works, this could offer a new treatment option for children with hard-to-treat low-grade gliomas, potentially shrinking tumors or keeping them from growing.
What could go wrong: This is a small, early-phase trial with only 25 children. The vaccine may not work for everyone, and side effects like fever or injection reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

low grade glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOW GRADE GLIOMA

Contacts and locations

Locations

Children's Hospital of Pittsburgh of UPMC
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.